Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25853657 | 0.86 | SMN1; SMN2 (0.44) | SMN1; SMN2USP2RECQLHSD17B10ATM | |
| SCHEMBL17293151 | 0.86 | SMN1; SMN2 (0.44) | SMN1; SMN2USP2RECQLHSD17B10ATM | |
| SCHEMBL17292975 | 0.86 | SMN1; SMN2 (0.44) | SMN1; SMN2USP2RECQLHSD17B10ATM | |
| SCHEMBL31379382 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2USP2RECQLHSD17B10ATM | |
| SCHEMBL31379341 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2USP2RECQLHSD17B10ATM | |
| SCHEMBL2737896 | 0.84 | MEN1 (0.48) | SMN1; SMN2USP2RECQLHSD17B10ATM | |
| SCHEMBL154453 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2RECQLHSD17B10ATM | |
| SCHEMBL186174 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2RECQLHSD17B10ATM | |
| SCHEMBL15116754 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2RECQLHSD17B10ATM | |
| SCHEMBL185522 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2RECQLHSD17B10ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SMN1; SMN2 4705/4885USP2 736/4885RECQL 1466/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SMN1; SMN2 4705/4885USP2 736/4885RECQL 1466/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | SMN1; SMN2 4657/4885USP2 861/4885RECQL 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.